3-D Matrix, Ltd. (DMTRF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
3-D Matrix, Ltd. (DMTRF) with AI Score 66/100 (Buy). 3-D Matrix, Ltd. specializes in self-assembling peptide technology, offering PuraMatrix for regenerative medicine and drug delivery. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 20263-D Matrix, Ltd. (DMTRF) Healthcare & Pipeline Overview
3-D Matrix, Ltd., founded in 2004, develops and commercializes PuraMatrix, a self-assembling peptide hydrogel used in regenerative medicine, cell therapy, and drug delivery, distinguishing itself through innovative biomaterial solutions within the competitive medical device landscape.
Investment Thesis
3-D Matrix, Ltd. presents a compelling investment thesis centered on its innovative PuraMatrix technology and its applications in the growing regenerative medicine and drug delivery markets. With a market capitalization of $0.48 billion and a P/E ratio of 46.99, the company demonstrates profitability with a 13.5% profit margin and a 70.6% gross margin. Growth catalysts include expanding applications of PuraMatrix in cell therapy and surgical treatments. Key value drivers include increasing adoption of PuraMatrix by research institutions and pharmaceutical companies, as well as potential partnerships for commercializing new applications. Potential risks include competition from established players in the biomaterials market and regulatory hurdles for new medical devices.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.48 billion indicates moderate investor interest in the company.
- P/E ratio of 46.99 suggests investors are paying a premium for each dollar of earnings, reflecting growth expectations.
- Profit margin of 13.5% demonstrates the company's ability to generate profit from its revenue.
- Gross margin of 70.6% indicates efficient production and pricing strategies.
- Beta of 0.52 suggests the stock is less volatile than the overall market.
Competitors & Peers
Strengths
- Proprietary self-assembling peptide technology
- Established brand recognition for PuraMatrix
- Strong relationships with research institutions
- High gross margin of 70.6%
Weaknesses
- Limited geographic reach
- Dependence on a single product (PuraMatrix)
- Small company size limits resources
- OTC market listing
Catalysts
- Upcoming: Expansion of PuraMatrix applications in cell therapy and regenerative medicine.
- Upcoming: Potential partnerships with pharmaceutical companies for drug delivery applications.
- Ongoing: Increasing adoption of PuraMatrix by research institutions.
- Ongoing: Development of new PuraMatrix-based surgical products.
- Ongoing: Strategic collaborations to expand market reach.
Risks
- Potential: Competition from established players in the biomaterials market.
- Potential: Regulatory hurdles for new medical devices.
- Potential: Economic downturn affecting research funding.
- Potential: Technological advancements rendering PuraMatrix obsolete.
- Ongoing: Limited geographic reach and dependence on a single product.
Growth Opportunities
- Expansion into Cell Therapy Market: The cell therapy market is experiencing rapid growth due to advancements in immunotherapy and stem cell research. PuraMatrix can be utilized as a scaffold for cell culture and delivery, enhancing the efficacy of cell-based therapies. This market is projected to reach $11.78 billion by 2029, offering a substantial growth opportunity for 3-D Matrix. The company can leverage its existing technology and partnerships to penetrate this market segment.
- Drug Delivery Applications: PuraMatrix can be used as a drug delivery system, providing controlled release and targeted delivery of therapeutic agents. The global drug delivery market is expected to reach $224.7 billion by 2027. 3-D Matrix can collaborate with pharmaceutical companies to develop new drug formulations using PuraMatrix, creating a significant revenue stream. This opportunity requires further research and development to optimize drug loading and release kinetics.
- Regenerative Medicine Applications: The regenerative medicine market is driven by the increasing prevalence of chronic diseases and the need for tissue repair and regeneration. PuraMatrix can be used as a scaffold for tissue engineering, promoting tissue regeneration in various applications, including wound healing and bone regeneration. The regenerative medicine market is projected to reach $57.6 billion by 2028, offering a significant growth opportunity for 3-D Matrix.
- Surgical Treatment Applications: PuraMatrix can be used in surgical procedures as a hemostat and tissue sealant. The global surgical sealant and hemostat market is expected to reach $4.3 billion by 2027. 3-D Matrix can develop and commercialize PuraMatrix-based surgical products, targeting specific surgical applications and collaborating with surgeons and hospitals. This opportunity requires clinical trials and regulatory approvals to demonstrate safety and efficacy.
- Partnerships and Collaborations: 3-D Matrix can pursue strategic partnerships and collaborations with research institutions, pharmaceutical companies, and medical device manufacturers to expand its market reach and accelerate product development. These partnerships can provide access to new technologies, markets, and funding opportunities. By collaborating with established players in the healthcare industry, 3-D Matrix can leverage its expertise in self-assembling peptide technology to create innovative solutions and drive growth.
Opportunities
- Expansion into new markets (e.g., Europe, North America)
- Development of new applications for PuraMatrix
- Strategic partnerships with pharmaceutical companies
- Increasing demand for regenerative medicine products
Threats
- Competition from established players in the biomaterials market
- Regulatory hurdles for new medical devices
- Economic downturn affecting research funding
- Technological advancements rendering PuraMatrix obsolete
Competitive Advantages
- Proprietary self-assembling peptide technology.
- Established brand recognition for PuraMatrix.
- Strong relationships with research institutions.
About DMTRF
3-D Matrix, Ltd., established in 2004 and based in Tokyo, Japan, is a biotechnology company focused on developing and commercializing self-assembling peptide technology. Its primary product, PuraMatrix, is a synthetic peptide hydrogel designed for various applications in regenerative medicine, cell therapy, drug delivery, and surgical treatments. PuraMatrix provides a three-dimensional environment that mimics the extracellular matrix, supporting cell growth, differentiation, and tissue regeneration. The company's technology aims to improve the efficacy and safety of medical treatments by providing a biocompatible and biodegradable scaffold for cellular therapies and drug delivery systems. 3-D Matrix operates primarily in Japan, with potential for expansion into other global markets through partnerships and direct sales. The company's competitive positioning relies on the unique properties of its self-assembling peptide technology and its potential to address unmet needs in regenerative medicine and drug delivery. 3-D Matrix continues to innovate and explore new applications for its core technology, aiming to establish itself as a leader in the field of biomaterials and regenerative medicine.
What They Do
- Develops self-assembling peptide technology.
- Offers PuraMatrix, a self-assembling peptide hydrogel.
- Provides solutions for regenerative medicine.
- Offers solutions for cell therapy.
- Provides solutions for drug delivery technology.
- Offers solutions for surgical treatment.
Business Model
- Develops and manufactures PuraMatrix.
- Sells PuraMatrix to research institutions and pharmaceutical companies.
- Collaborates with partners to develop new applications for PuraMatrix.
Industry Context
3-D Matrix, Ltd. operates within the medical device industry, specifically focusing on biomaterials and regenerative medicine. The global regenerative medicine market is projected to reach $57.6 billion by 2028, growing at a CAGR of 21.8% from 2021. This growth is driven by increasing demand for cell-based therapies, gene therapies, and tissue engineering products. The competitive landscape includes companies like ABTI, AONC, CMVLF, EAPIF, and EDTXF, as well as larger players in the biomaterials and medical device sectors. 3-D Matrix differentiates itself through its self-assembling peptide technology, offering unique advantages in cell culture, drug delivery, and tissue regeneration.
Key Customers
- Research institutions
- Pharmaceutical companies
- Hospitals
Financials
Chart & Info
3-D Matrix, Ltd. (DMTRF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 27, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DMTRF.
Price Targets
Wall Street price target analysis for DMTRF.
MoonshotScore
What does this score mean?
The MoonshotScore rates DMTRF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jun Okada
CEO
Jun Okada serves as the CEO of 3-D Matrix, Ltd., leading the company in its development and commercialization of self-assembling peptide technology. His background includes experience in biotechnology and business management. He has been instrumental in guiding the company's strategic direction, fostering innovation, and building partnerships to expand the applications of PuraMatrix. Okada's leadership focuses on driving growth and creating value for shareholders through the successful execution of the company's business plan.
Track Record: Under Jun Okada's leadership, 3-D Matrix has achieved key milestones in the development and commercialization of PuraMatrix. He has overseen the expansion of PuraMatrix applications in regenerative medicine, cell therapy, drug delivery, and surgical treatments. Okada has also focused on building strategic partnerships with research institutions and pharmaceutical companies to accelerate product development and market penetration. His leadership has contributed to the company's growth and profitability.
DMTRF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that 3-D Matrix, Ltd. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available to the public, and trading activity can be sporadic. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Lower trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or scams
- Lack of regulatory oversight
- Verify the company's financial statements (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review any available news and press releases about the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- Check for any regulatory actions or legal issues involving the company.
- Established business operations since 2004.
- Proprietary self-assembling peptide technology.
- PuraMatrix product with applications in regenerative medicine.
- Relationships with research institutions.
- Managing 106 employees.
3-D Matrix, Ltd. Stock: Key Questions Answered
What does 3-D Matrix, Ltd. do?
3-D Matrix, Ltd. develops and commercializes self-assembling peptide technology, primarily focusing on its PuraMatrix product. PuraMatrix is a synthetic peptide hydrogel used in regenerative medicine, cell therapy, drug delivery, and surgical treatments. The company's technology provides a three-dimensional environment that mimics the extracellular matrix, supporting cell growth, differentiation, and tissue regeneration. 3-D Matrix aims to improve the efficacy and safety of medical treatments by providing a biocompatible and biodegradable scaffold for cellular therapies and drug delivery systems, targeting research institutions, pharmaceutical companies, and hospitals.
What do analysts say about DMTRF stock?
AI analysis is currently pending for DMTRF. However, based on available financial data, 3-D Matrix, Ltd. has a market capitalization of $0.48 billion and a P/E ratio of 46.99, suggesting investors have high growth expectations. The company's profit margin is 13.5%, and its gross margin is 70.6%. As an OTC stock, DMTRF carries higher risks compared to stocks listed on major exchanges due to limited financial disclosure and lower trading volume. Investors should conduct thorough due diligence before investing in DMTRF.
What are the main risks for DMTRF?
The main risks for 3-D Matrix, Ltd. include competition from established players in the biomaterials market, regulatory hurdles for new medical devices, and the potential for an economic downturn affecting research funding. Additionally, technological advancements could render PuraMatrix obsolete. As an OTC stock, DMTRF faces risks related to limited financial disclosure, lower trading volume, and the potential for price manipulation. The company's dependence on a single product (PuraMatrix) and its limited geographic reach also pose risks to its growth and profitability.
What are the key factors to evaluate for DMTRF?
3-D Matrix, Ltd. (DMTRF) currently holds an AI score of 66/100, indicating moderate score. Key strength: Proprietary self-assembling peptide technology. Primary risk to monitor: Potential: Competition from established players in the biomaterials market.. This is not financial advice.
How frequently does DMTRF data refresh on this page?
DMTRF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DMTRF's recent stock price performance?
Recent price movement in 3-D Matrix, Ltd. (DMTRF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary self-assembling peptide technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DMTRF overvalued or undervalued right now?
Determining whether 3-D Matrix, Ltd. (DMTRF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DMTRF?
Before investing in 3-D Matrix, Ltd. (DMTRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- AI analysis is pending and may provide additional insights.
- OTC market investments carry higher risks.